reports
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share
NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share BOCA RATON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- (“the Company”) (NASDAQ: NEWT) announced that its Board of Directors declared a quarterly cash dividend of $0.19 per share on the outstanding common stock of NewtekOne. The dividend is payable on July 21, 2025, to shareholders of record as of July 9, 2025. Note Regarding Dividend Payments Amount and timing of dividends, if any, remain subject to the discretion of the Company's Board of Directors. About NewtekOne, Inc. , Your Business Solutions Company®,...
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain ...
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. “Alzheimer’s & Brain Awareness Month offers the perfect opportunity for all...
NewtekOne, Inc. Upsizes Warehouse Facility to Support Growth of ALP Bu...
NewtekOne, Inc. Upsizes Warehouse Facility to Support Growth of ALP Business BOCA RATON, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) announced today that its consolidated subsidiary, Newtek ALP Holdings, amended and upsized its revolving credit facility with Deutsche Bank AG (“DB”), which facility is employed to fund the origination of Alternative Loan Program (“ALP”) loans before they are placed into securitizations. The amendment provides for, among other things, a facility increase to $170 million. DB has been an ALP warehouse lender to the Company since 201...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam ...
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society (AHS), being held June 19-22, 2025, ...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness M...
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, is proud to recognize Migraine and Headache Awareness Month alongside the Association of Migraine Disorders. In honor of this year’s theme, “Your Path to Better Days,” Axsome is supporting more than a dozen events across the U.S. throughout the month of June and beyond. Axsome i...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multip...
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the ...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and...
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) ...
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not su...
Corcept Therapeutics Inc: 3 directors
Three Directors at Corcept Therapeutics Inc sold after exercising options/sold 65,000 shares at between 78.044USD and 82.858USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
NewtekOne, Inc. to Report Second Quarter 2025 Results and Host a Confe...
NewtekOne, Inc. to Report Second Quarter 2025 Results and Host a Conference Call on Monday, July 28, 2025 BOCA RATON, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) will report its second quarter 2025 financial results after the market closes on Monday, July 28, 2025. A conference call to discuss these results will be hosted by Barry Sloane, Chief Executive Officer, Frank DeMaria, Chief Financial Officer of NewtekOne, and M. Scott Price, Chief Financial Officer of Newtek Bank, N.A., at 4:30 pm ET on Monday, July 28, 2025. Barry Sloane, Chairman, President, and Ch...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Axsome Therapeutics Inc: 2 directors
Two Directors at Axsome Therapeutics Inc sold after exercising options/sold 48,173 shares at between 104.065USD and 104.450USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June: William Blair 45th Annual Growth Stock ConferenceThe Company will present on Tuesday, June 3, 2025, at 10:40 a.m. CT in Chicago, IL Jefferies Global Healthcare ConferenceThe Company will present on Thursday, June 5, 2025, at 2:35 p.m. ET in New ...
Axsome Therapeutics Presents Data from Three of Its Innovative Neurosc...
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations from three of its innovative neuroscience programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting, being held from May 27-30 in Scottsdale, Arizona. Details of the present...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation w...
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey...
- Jonathan Moreland
TRS TRIMAS CORPORATION
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
GLP GLOBAL PARTNERS LP
PATK PATRICK INDUSTRIES INC.
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
ELY CALLAWAY GOLF COMPANY
FLWS 1-800-FLOWERS.COM CL A
GBLI GLOBAL INDEMNITY PLC
SNDX SYNDAX PHARMACEUTICALS
HAIN THE HAIN CELESTIAL GROUP
NHF INC.
BRT NEXPOINT CREDIT STRATEGIES FUN
OCSL BRT APARTMENTS
MPB OAKTREE SPECIALTY LENDING CORPORATION
FGBI MID PENN BANCORP INC.
MIDD FIRST GUARANTY BANCSHARES
ENR THE MIDDLEBY CORPORATION
AVTR EDGEWELL PERSONAL CARE COMPANY
ZYME AVANTOR
VLA INC.
ONEW ZYMEWORKS INC.
ADV ARBOR METALS
DLHC ONEWATER MARINE
CVRX ADVANTAGE SOLUTIONS INC (A)
PFBX DALEIGH HOLDINGS CORP
TCRX CVRX
STGW INC.
OPAL PEOPLES FINANCIAL CORP. (MISSISSIPPI)
PRME FIRST EAGLE ALTERNATIVE CAPITAL BDC INC
STRW STAGWELL INC
PHIN OPAL FUELS INC
SRBK PRIME MEDICINE INC
SDHC STRAWBERRY FIELDS REIT INC.
FIP PHINIA INC
SUNS SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO FTAI INFRASTRUCTURE INC
GF SUNRISE REALTY TRUST
FG EATON VANCE INSD CALIF MUN BD FD
GREE MORNINGSTAR PARTNERS
HCWB L.P.
IAE THE NEW GERMANY FUND
FINS INC.
F AND G ANNUITIES AND LIFE
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
ANGEL OAK FINANCIAL STRATEGIES INCOME TERM TRUST
- Jonathan Moreland
MMLP MARTIN MIDSTREAM PARTNERS L.P.
JRVR JAMES RIVER GROUP HOLDINGS LTD
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
BBDC BARINGS BDC INC.
ENR EDGEWELL PERSONAL CARE COMPANY
INZY INOZYME PHARMA
ALIT ALIGHT
WEST INC. / DELAWARE
STRW WESTROCK COFFEE COMPANY LLC
SRBK STRAWBERRY FIELDS REIT INC.
SDHC SR BANCORP INC
EVM SMITH DOUGLAS HOMES CORP
TXO EATON VANCE INSD CALIF MUN BD FD
GF MORNINGSTAR PARTNERS
GREE L.P.
HCWB THE NEW GERMANY FUND
INC.
GREENIDGE GENERATION HLDGS INC
HCW BIOLOGICS INC
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
LTRX LANTRONIX INC.
BRKR BRUKER CORPORATION
OFIX ORTHOFIX INTERNATIONAL N.V.
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
THS TREEHOUSE FOODS INC.
WINA WINMARK CORP.
AMBC AMBAC FINANCIAL GROUP INC.
NNBR NN
HAIN INC.
SNBR THE HAIN CELESTIAL GROUP
LILA INC.
COLD SLEEP NUMBER CORPORATION
ULBI LIBERTY LATIN AMERICA A
MIDD AMERICOLD REALTY TRUST
CCO ULTRALIFE
PRG THE MIDDLEBY CORPORATION
LESL CLEAR CHANNEL OUTDOOR HOLDINGS INC
KLXE PROG HOLDINGS
CVRX INC.
MYO LESLIES
SEAT KLX ENERGY SERVICES
DCGO CVRX
PFHC INC.
MYOMO
VIVID SEATS INC.
DOCGO INC
PROFRAC HLDG CORP
- Jonathan Moreland
OEC ORION ENGINEERED CARBONS SA
LTRX LANTRONIX INC.
LGND LIGAND PHARMACEUTICALS INCORPORATED
NEWT NEWTEK BUSINESS SERVICES INC.
HTLD HEARTLAND EXPRESS INC.
UEIC UNIVERSAL ELECTRONICS INC.
VSH VISHAY INTERTECHNOLOGY INC.
FLL FULL HOUSE RESORTS INC.
FLWS
NINE 1-800-FLOWERS.COM CL A
CNX NINE ENERGY SERVICE INC
A2H9KJ CONSOL ENERGY INC.
TCPC NEO PERFORMANCE MATERIAL
MIDD BLACKROCK TCP CAPITAL CORP.
ENR THE MIDDLEBY CORPORATION
PHAT EDGEWELL PERSONAL CARE COMPANY
DLHC PHATHOM PHARMACEUTICALS
MINM DALEIGH HOLDINGS CORP
STGW MINIM
NVCT INC.
PFHC STAGWELL INC
RXO_w NUVECTIS PHARMA INC
FTK PROFRAC HLDG CORP
NCDL RXO INC
DMA FLOTEK INDUSTRIES INC.
GF NUVEEN CHURCHILL DIRECT LENDING CORP
IAE DESTRA MULTI ALTERNATIVE FUND
THRM THE NEW GERMANY FUND
AESI INC.
ING ASIA PACIFIC HIGH DIVIDEND EQUITY INCOME FUND
SOLTA MEDICAL, INC
ATLAS ENERGY SOLUTIONS INC.
NewtekOne Inc: 3 directors
A director at NewtekOne Inc bought 5,000 shares at 11.068USD and the significance rating of the trade was 41/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.